PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10901374-11	2000	5-FU/folinic acid alone did not induce TP activity but a single dose of IFNalpha led to upregulation of TP within 2 h of administration with a further increase by 24 h (signed rank test, P = 0.006).	Leucovorin	5-17	interferon alpha 1	Homo sapiens	72-80	
9589033-6	1998	IFN-alpha has shown therapeutic efficiency when combined with 5-FU alone or with 5-FU and leucovorin, but latest studies with these combinations have shown increased toxicity.	Leucovorin	90-100	interferon alpha 1	Homo sapiens	0-9	
10762745-1	2000	The aim of this study was to evaluate the efficacy and toxicity of ifosfamide, 5-fluorouracil (5-FU) and leucovorin (IFL) as a second-line chemotherapy regimen in patients with recurrent undifferentiated nasopharyngeal carcinoma (NPC) previously treated with platinum/5-FU.	Leucovorin	105-115	interferon alpha 1	Homo sapiens	117-120	
7577043-3	1995	These preclinical studies stimulated clinical evaluation of IFN-alpha in combination with 5-fluorouracil (5-FU) with and without leucovorin (LV), and the initial clinical results appeared promising.	Leucovorin	129-139	interferon alpha 1	Homo sapiens	60-69	
9070485-3	1997	Clinical trials have shown debatable results when IFN is given in high doses with 5-FU used as a bolus alone or in combination with leucovorin (LV).	Leucovorin	144-146	interferon alpha 1	Homo sapiens	50-53	
8862717-10	1996	Our results show that doses of IFN of 18 MU/m2 given by a 24 h infusion can be administered safely to an established and active schedule of weekly 24 h infusion of 5-FU and LV.	Leucovorin	173-175	interferon alpha 1	Homo sapiens	31-34	
9020295-2	1997	A phase I-II clinical trial was initiated to treat several tumor types with IFN-alpha-2b, cisplatin, 5-FU, and leucovorin (LV), given daily for 5 days of a 28-day cycle.	Leucovorin	123-125	interferon alpha 1	Homo sapiens	76-79	
8983929-2	1995	The influence of interferon (IFN) coadministered subcutaneously with the biomodulating agent folinic acid on the blood serum levels of 5-formyl-tetrahydrofolic acid (CHO-THFA) and the biotransformation into its main metabolite in the blood 5-methyltetrahydrofolic acid (CH3-THFA) was studied in patients receiving a chemotherapy with 5-fluorouracil.	Leucovorin	135-164	interferon alpha 1	Homo sapiens	17-27	
8983929-2	1995	The influence of interferon (IFN) coadministered subcutaneously with the biomodulating agent folinic acid on the blood serum levels of 5-formyl-tetrahydrofolic acid (CHO-THFA) and the biotransformation into its main metabolite in the blood 5-methyltetrahydrofolic acid (CH3-THFA) was studied in patients receiving a chemotherapy with 5-fluorouracil.	Leucovorin	135-164	interferon alpha 1	Homo sapiens	29-32	
7611752-6	1995	An attempt to add leucovorin (LV) to the combination of 5-FU and IFN has so far appeared less successful.	Leucovorin	18-28	interferon alpha 1	Homo sapiens	65-68	
7611752-6	1995	An attempt to add leucovorin (LV) to the combination of 5-FU and IFN has so far appeared less successful.	Leucovorin	30-32	interferon alpha 1	Homo sapiens	65-68	
7577043-3	1995	These preclinical studies stimulated clinical evaluation of IFN-alpha in combination with 5-fluorouracil (5-FU) with and without leucovorin (LV), and the initial clinical results appeared promising.	Leucovorin	141-143	interferon alpha 1	Homo sapiens	60-69	
14569847-2	2003	It has antitumor efficacy as a single agent, and also has been combined with fluorouracil (5-FU) and leucovorin (IFL) to treat these patients.	Leucovorin	101-111	interferon alpha 1	Homo sapiens	113-116	
8192103-6	1994	In conclusion, our study demonstrates that IFN-alpha 2B at doses higher than 6 x 10(6) IU intramuscularly three times per week in the combination with 5-fluorouracil and folinic acid we used is too toxic for the majority of patients; this combination has moderate activity in metastatic colorectal cancer, although similar response rates have been reported, with less toxicity, with 5-fluorouracil plus folinic acid without IFN-alpha.	Leucovorin	170-182	interferon alpha 1	Homo sapiens	43-52	
8192103-6	1994	In conclusion, our study demonstrates that IFN-alpha 2B at doses higher than 6 x 10(6) IU intramuscularly three times per week in the combination with 5-fluorouracil and folinic acid we used is too toxic for the majority of patients; this combination has moderate activity in metastatic colorectal cancer, although similar response rates have been reported, with less toxicity, with 5-fluorouracil plus folinic acid without IFN-alpha.	Leucovorin	403-415	interferon alpha 1	Homo sapiens	43-52	
8174205-9	1994	In conclusion, without substantially increasing the toxicity, IFN can be added to the etoposide/leucovorin/5-fluorouracil combination, at a dose of 3 MU/m2.	Leucovorin	96-106	interferon alpha 1	Homo sapiens	62-65	
8426214-2	1993	PATIENTS AND METHODS: Escalating doses of IFN (0.5 to 4.0 x 10(6) U/m2/d x 6) were added to cisplatin 100 mg/m2, continuous infusion 5-FU 800 or 640 mg/m2/d x 5, and leucovorin 100 mg orally every 4 hours.	Leucovorin	166-176	interferon alpha 1	Homo sapiens	42-45	
15565917-1	2004	Rothenberg et al called for caution in the palliative use of irinotecan, 5-fluorouracil (5-FU) bolus and leucovorin (IFL schedule), because of early treatment related deaths in C89803 and N9741 studies.	Leucovorin	105-115	interferon alpha 1	Homo sapiens	117-120